MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
Globe Newswire•16/11/2026•08:00 ET
1
Key Highlights
- ➤December 2, 2026 KOL event will address EscharEx Phase III VALUE study
- ➤EscharEx targets debridement and wound closure in chronic wounds
- ➤$1.05 billion estimated U.S. annual peak sales potential
- ➤Phase III VALUE trial underway in venous leg ulcers
- ➤Future studies planned in diabetic foot and pressure ulcers
MediWound to Host Virtual KOL Event on EscharEx(®) Phase III VALUE Study and Commercial Opportunity on December 2, 2026
Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential
Get started
Create a free account to read the full story.
